Drug Approval | March 12, 2026
FDA nod to first treatment for rare genetic brain disorder
The approval comes after a systematic review of published literature
The approval comes after a systematic review of published literature
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
Subscribe To Our Newsletter & Stay Updated
